

Ngrazier 10781442clm1and6

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

114.85

450.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-15.00

-15.00

STN INTERNATIONAL LOGOFF AT 09:57:24 ON 10 JAN 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAPplus-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of CAPplus documents for use in third-party analysis and
visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAPplus - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16 DEC 14 CA/CAPplus to be enhanced with updated IPC codes
NEWS 17 DEC 16 MARPATprev will be removed from STN on December 31, 2005
NEWS 18 DEC 21 IPC search and display fields enhanced in CA/CAPplus with the
IPC reform
NEWS 19 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS DCOST SINCE APPROXIMATELY 20:00 COLUMBUS TIME DECEMBER 29,
SOME ONLINE COST DISPLAYS HAVE BEEN SHOWING COSTS IN
2006 PRICES FOR STN COLUMBUS FILES. THIS HAS BEEN
CORRECTED. PLEASE BE ASSURED THAT YOU WILL BE BILLED
ACCORDING TO 2005 PRICES UNTIL JAN 1. PLEASE CONTACT
YOUR LOCAL HELP DESK IF YOU HAVE ANY QUESTIONS. WE
APOLOGIZE FOR THE ERROR.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

*IFICDB - The IFI Comprehensive Database from 1950-present
 *IFIPAT - The IFI Patent Database from 1950-present
 *IFIUDB - The IFI Uniterm Database from 1950-present

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 09:50:51 ON 10 JAN 2006

=> fil reg

| | | |
|----------------------|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 0.42 | 0.42 |

FILE 'REGISTRY' ENTERED AT 09:51:55 ON 10 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JAN 2006 HIGHEST RN 871542-42-6
 DICTIONARY FILE UPDATES: 9 JAN 2006 HIGHEST RN 871542-42-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

 *
 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *
 *



Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10781442clm1to3.str



chain nodes :

7 8 9 10

ring nodes :

1 2 3 4 5 6 13 14 15 16 17

chain bonds :

2-7 7-8 8-9 8-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-17 14-15 15-16 16-17

exact/norm bonds :

2-7 7-8 8-9 8-10 13-14 13-17 14-15 15-16 16-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:N,SO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS

13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

Element Count :

Node 9: Limited

C,C4


S,S1

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS


L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10781442clm6and8.str



chain nodes :

7 8 9 10 11 18

ring nodes :

1 2 3 4 5 6 12 13 14 15 16 17

chain bonds :

2-7 7-8 8-9 8-18 9-10 10-11 11-12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

exact/norm bonds :

2-7 7-8 8-9 8-18 9-10 10-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

G1:N, SO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS

11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

Element Count :

Node 9: Limited

C, C4


S, S1

L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS

L2 STR



G1 N,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 09:52:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 43651 TO ITERATE

4.6% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 860549 TO 885491
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 09:52:46 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 871498 TO ITERATE

100.0% PROCESSED 871498 ITERATIONS
SEARCH TIME: 00.00.11

157 ANSWERS

L4 157 SEA SSS FUL L1

=> s 12

SAMPLE SEARCH INITIATED 09:53:07 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 48018 TO ITERATE

4.2% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.03

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 947287 TO 973433
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L2

=> s 12 full

FULL SEARCH INITIATED 09:53:16 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 962273 TO ITERATE

100.0% PROCESSED 962273 ITERATIONS
SEARCH TIME: 00.00.13

300 ANSWERS

L6 300 SEA SSS FUL L2

=> filhcaplus

FILHCAPLUS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

334.76

335.18

FILE 'HCAPLUS' ENTERED AT 09:54:09 ON 10 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jan 2006 VOL 144 ISS 3

FILE LAST UPDATED: 9 Jan 2006 (20060109/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4

L7 9 L4

=> d ed abs ibib hitstr 1-9

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Mar 2005
GI



AB The invention relates to a preparation of urotensin II receptor antagonists and CCR-9 antagonists of formula I [wherein: R1, R2, and R3 are independently selected from H, halogen, alkyl, aryl, or CN, etc.; X is CH2, O, or NH, etc.; Y is SO2, C(O), CH2SO2, NHC(O), or NHSO2, etc.; T and W are independently selected from H, (cyclo)alkyl, alkoxyl, aryl, or halogen, etc.; R4 is aryl, heterocyclyl, or cycloalkyl]. For instance, thiophenecarboxamide derivative II was prepared via amidation of thiophene-2-carboxylic acid by [2,4,6-trimethyl-3-(pyrrolidin-1-yl)phenyl]amine. The invention compds. were tested for inhibition of human urotensin II-induced Ca²⁺ mobilization in UTR cells (IC50 > 0.5 μM).

ACCESSION NUMBER: 2005:185392 HCAPLUS
DOCUMENT NUMBER: 142:280229
TITLE: A preparation of urotensin II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, C. Eric; Bui, Huong; Gao, Dakin; Kassir, Jamal; Li, Wen; Wang, Junmei; Biediger, Ronald; Chen, Jie; Market, Robert V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 781,442.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| US 2005049286 | A1 | 20050303 | US-2004-924180 | 20040823 |
| US 2004180892 | A1 | 20040916 | US 2004-781442 | 20040218 |


L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PRIORITY APPL. INFO.: US 2003-448791P P 20030220
US 2004-781442 A2 20040218

OTHER SOURCE(S): MARPAT 142:280229


IT 749266-71-5P 749268-37-9P 749268-38-0P
847414-22-6P 847414-23-7P 847414-24-8P
847414-25-9P 847414-30-6P 847414-31-7P
847414-33-9P 847414-34-0P 847414-35-1P
847414-36-2P 847414-37-3P 847414-38-4P
847414-39-5P 847414-40-8P 847414-41-9P
847414-42-0P 847414-43-1P 847414-44-2P
847414-45-3P 847414-46-4P 847414-47-5P
847414-48-6P 847414-49-7P 847414-50-0P
847414-51-1P 847414-52-2P 847414-53-3P
847414-54-4P 847414-55-5P 847414-56-6P
847414-57-7P 847414-58-8P 847414-59-9P
847414-60-2P 847414-61-3P 847414-62-4P
847414-63-5P 847414-64-6P 847414-62-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of urotensin II receptor antagonists and CCR-9 antagonists)
RN 749266-71-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 749268-37-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 749268-38-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847414-22-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(methoxymethyl)(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-23-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(3-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-24-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-25-9 HCAPLUS


L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, 3-[(methylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-30-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(3-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-31-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(2-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-33-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(3-methoxyphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847414-34-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-methylphenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-35-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-methylphenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-39-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-40-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-41-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847414-36-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-methoxyphenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-37-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-chlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-38-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-42-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-chlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-43-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-chlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-44-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847414-45-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-46-4 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[4-fluorophenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-47-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[2-bromophenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-48-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3,5-dichlorophenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847414-49-7 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3,5-difluorophenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-50-0 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3,4-dichlorophenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-51-1 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3,4-difluorophenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847414-52-2 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3-chloro-4-fluorophenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-53-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3,4,5-trifluorophenyl]sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 847414-54-4 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(4-fluorobenzoyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-55-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 2-[(4-fluorobenzoyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-56-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-57-7 HCAPLUS
 CN 3-Thiophenecarboxamide, 4-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 847414-61-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[2,4-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-62-4 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[(2-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-63-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[(3-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-64-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[(3-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847414-58-8 HCAPLUS
 CN 3-Thiophenecarboxamide, 4,5-dimethyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-59-9 HCAPLUS
 CN 3-Thiophenecarboxamide, 4-methyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-60-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[2,6-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 847414-82-8 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[methyl(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



IT 847414-29-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of urotensin II receptor antagonists and CCR-9 antagonists)
 RN 847414-29-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-amino-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Sep 2004
G1




AB The title compds. I and II (R1, R2, R3 = H, halo, alkyl, aryl, aralkyl, CN, CF3, etc.; X = N, CH2, or O; Y = SO2, CO, CH2SO2, CH2CO, NHCO, OCO, or NHSO2; R4 = alkyl, aralkyl or (hetero)aryl, R5 = R1, or 2-NR7R8, or R4, R5 taken together with W can form a 5 or 6 membered ring; Z = (CH2)n, where n = 0-6; R6 = (hetero)aryl, 2-NR7R8; R7, R8 = H, alkyl, aryl, aralkyl or together with N form a pyrrolidine, piperazine, piperidine, or morpholine ring; E = substituted amino, O, S, CR13-CR14, or CR13=N, where R13, R14 = alkyl, (hetero)aryl, halo, OH, alkoxy, etc.; D = substituted amino, O, or S; Z = NR15 or CR15R16 where each R15 = H, alkyl, aryl, or heteroaryl; A = (substituted)amino, CO, or SO2; when A = (substituted)amino, B = SO2, CO2, or CIGR16, where R16 = H, alkyl, aryl, or heteroaryl; when A = CO or SO2, B = (substituted)amino; R9, R10 = H, alkyl, (hetero)aryl, halo, OH, Alkoxy, or (substituted)amino; R11, R12 = H, alkyl, or (hetero)aryl were prepared as urotensin-II receptor antagonists and CCR-9 antagonists for the treatment of congestive heart failure, stroke, ischemic heart disease, etc. For example, reaction of 2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylamine (preparation given) with 1-naphthalenesulfonyl chloride yielded compound III. The latter showed an IC50 = 10 µM in the assay of human urotensin-II-induced Ca2+ mobilization in UTR cells.

ACCESSION NUMBER: 2004:718308 HCAPLUS
DOCUMENT NUMBER: 141:243188
TITLE: Preparation of phenylenediamine and thiophene carboxylic amide derivatives as urotensin-II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, Eric C.; Bui, Huong; Gao, Damin; Kassir, Jamal; Li, Wen; Wang, Junmei; Market, Robert V.
PATENT ASSIGNEE(S): Encysive Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 84 pp.


L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 749267-43-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-bromo-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-37-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004071634 | A2 | 20040802 | WO 2004-US4645 | 20040218 |
| V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, QA, RO, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, SR, SS, ST, SV, SY, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2515780 | A1 | 20040902 | CA 2004-2515780 | 20040218 |
| EP 1610753 | A2 | 20060104 | EP 2004-712313 | 20040218 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRIORITY APPLN. INFO.: | | | US 2003-448791P | P 20030220 |
| | | | WO 2004-US4645 | W 20040218 |

OTHER SOURCE(S): MARPAT 141:243188
IT 749266-71-5P 749267-36-5P 749267-43-4P
749268-37-9P, 3-Phenylaminosulfonyl-N-[2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl]-thiophene-2-carboxamide 749268-38-0P, 3-Benzenesulfonylamino-N-[2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl]-thiophene-2-carboxamide
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of phenylenediamine and thiophene carboxylic amide derivs. as urotensin-II receptor antagonists and CCR-9 antagonists)
RN 749266-71-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749267-36-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-phenyl-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 26 Aug 2004
G1



AB Title compds. (I; R1, R2 = H, alkyl, alkoxyalkyl, aryloxyalkyl, alkylcarbonyl, alkenylcarbonyl, etc.; R1R2N = atoms to form a 4-10 membered mono-, bi-, or spirocyclic (substituted) ring; R3 = H, alkyl; R4, R5 = H, alkyl, OH, alkoxy, alkylcarbonyloxy, alkylthio; R6-R9 = H, alkyl; R6R7, R8R9 = O, A, B, D, G = N, CR42; AB, DO = CR42; R42 = H, F, Cl, Br, Iodo, CF3, NO2, cyano, OCF3, alkoxy, alkylthio, alkenyl, cycloalkyl, cycloalkoxy, cycloalkenyl, alkynyl, CO2H, etc.; R10 = H, alkyl, alkenyl, alkynyl; X = NR52, O, bond, C-C, C-tpbond, C, etc.; R52 = H, alkyl; E = (substituted) C3-14 carbocyclic, heterocyclic; K = bond, O, CH2O, S, SO, CO, C-C, C-tpbond, C, etc.; R11 = H, alkyl, alkoxyalkyl, alkenyl, alkynyl, 3-10 membered (substituted) mono-, bi-, tri- or spirocyclic ring; EKR11 = (unsatd.) tricyclic ring; m, n = 0-2), were prepared Thus: N-[1-(4-aminophenyl)pyrrolidin-3-yl]piperidine was treated with carbonyldiimidazole and then with 4-(4-chlorophenyl)piperidine to give 4-(4-chlorophenyl)piperidine-1-carboxylic acid [4-[3-(acetylthylamino)pyrrolidin-1-yl]phenyl]amide. The latter at 30 mg/kg orally in female NMRI mice reduced milk consumption by 64%.

ACCESSION NUMBER: 2004:696342 HCAPLUS
DOCUMENT NUMBER: 141:225302
TITLE: Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.
INVENTOR(S): Schwink, Lothar; Stangelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Stahl, Petra; Grotzke, Dirk
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 390 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2004072025 | A2 | 20040826 | WO 2004-EP1342 | 20040213 |
| WO 2004072025 | A3 | 20041223 | | |
| V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, QA, RO, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, SR, SS, ST, SV, SY, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10306250 | A1 | 20040903 | DE 2003-10306250 | 20030214 |
| CA 2516118 | AA | 20040826 | CA 2004-2516118 | 20040213 |
| EP 1597228 | A2 | 20051123 | EP 2004-710809 | 20040213 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 US 2004220191 A1 20041104 US 2004-779853 20040217
 PRIORITY APPLN. INFO.: DE 2003-10306250 A 20030214
 US 2003-488545P P 20030718
 WO 2004-EP1342 W 20040213

OTHER SOURCE(S): MARPAT 141:225302


IT 748167-93-3P 748167-96-6P 748169-24-5P
 748172-14-7P 748173-15-1P 748173-46-8P
 748173-47-9P 748173-58-2P 748173-65-1P
 748174-48-3P 748176-31-0P 748177-24-4P
 748178-96-3P 748178-97-4P 748178-98-5P
 748181-67-1P 748182-41-4P 748182-42-5P
 748182-43-6P 748182-44-7P 748182-45-8P
 748182-46-9P 748182-47-0P 748182-48-1P
 748182-49-2P 748182-50-5P 748182-51-6P
 748182-52-7P 748182-53-8P 748182-54-9P
 748182-55-0P 748182-56-1P 748182-57-2P
 748182-58-3P 748182-59-4P 748182-60-7P
 748182-61-8P 748182-62-9P 748182-63-0P
 748182-64-1P 748182-65-2P 748182-66-3P
 748182-67-4P 748182-68-5P 748182-69-6P
 748182-70-9P 748182-71-0P 748182-72-1P
 748182-73-2P 748182-76-5P 748182-81-2P
 748182-82-3P 748182-83-4P 748182-84-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-arylheterocycles as MCH antagonists)


RN 748167-93-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3-(acetylmethylamino)-1-pyrrolidinyl]phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 748167-96-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3-(acetylmethylamino)-1-pyrrolidinyl]phenyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 748169-24-6 HCAPLUS

CN 2-Thiophenecarboxamide, 5-(2,4-difluorophenyl)-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CH 1

CRN 748169-23-5
 CMF C23 H23 F2 N3 O S



PAGE 1-A



PAGE 2-A

CH 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 748172-14-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 748173-15-1 HCAPLUS

CN Carbamic acid, methyl[1-[4-[[[4-(2-methyl-5-thiazolyl)-2-thienyl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 748173-46-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 748173-47-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)




RN 748173-58-2 HCAPLUS

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 748173-65-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A

RN 748174-48-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 4-[(4-chlorophenyl)sulfonyl]-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748176-31-0 HCAPLUS
 CN 2-Thiophenecarboxamide, 4-(4-chlorophenyl)-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A


PAGE 2-A

RN 748177-24-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 748178-96-3 HCAPLUS
 CN Carbamic acid, methyl[1-[4-[[[5-(2-pyridinylethynyl)-2-thienyl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 748178-97-4 HCAPLUS
 CN Carbamic acid, [1-[4-[[[5-[(4-fluorophenyl)ethynyl]-2-thienyl]carbonyl]amino]phenyl]-3-pyrrolidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748178-98-5 HCAPLUS
 CN Carbamic acid, methyl[1-[4-[[[5-(3-pyridinylethynyl)-2-thienyl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 748181-67-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-(2-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)




RN 748182-41-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 748182-42-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-45-8 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(3-ethoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 748182-43-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(3-methoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-44-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 748182-46-9 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(4-ethoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A

RN 748182-47-0 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(4-cyanophenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



PAGE 1-A


NMe

RN 748182-48-1 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(3,4-dimethoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 2-A


NMe

RN 748182-50-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(2-acetylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

NMe


RN 748182-49-2 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(4-acetylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 748182-51-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(1,3-benzodioxol-5-yl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-52-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 748182-53-8 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-[4-(ethylthio)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




NMe

PAGE 2-A

RN 748182-54-9 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(4-ethylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




NMe

PAGE 2-A

RN 748182-55-0 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(3,4-dimethylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




NMe

PAGE 2-A

RN 748182-56-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[4-(2-methyl-2-propoxy)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




NMe

PAGE 2-A

RN 748182-57-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 748182-58-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methyldimethylamino)-1-pyrrolidinyl]phenyl]-5-[3-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)


NMe

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748182-59-4 HCAPLUS
 CN Benzoic acid, 4-[5-[[[4-[3-(methyldimethylamino)-1-pyrrolidinyl]phenyl]amino]carboxylic acid, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



RN 748182-60-7 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(6-methoxy-3-pyridinyl)-N-[4-[3-(methyldimethylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-61-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methyldimethylamino)-1-pyrrolidinyl]phenyl]-5-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 748182-62-9 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-[2-(acetylamino)phenyl]-N-[4-[3-(methyldimethylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748182-63-0 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(3,5-dimethyl-4-isoxazolyl)-N-[4-[3-(methyldimethylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-64-1 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(6-fluoro-3-pyridinyl)-N-[4-[3-(methyldimethylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 748182-65-2 HCAPLUS
 CN Benzoic acid, 3-[5-[[[4-(3-(methylamino)-1-pyrrolidinyl)phenyl]amino]carbo-
 nyl]-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 748182-66-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(4-cyclohexylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748182-67-4 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-[4-(acetylamino)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748182-68-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-[(dimethylamino)carbonyl]phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 748182-69-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-[4-[(dimethylamino)carbonyl]phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 748182-70-9 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-[4-(dimethylamino)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 748182-71-0 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-72-1 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(3-acetylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-73-2 HCAPLUS
 CN [2,2'-Bithiophene]-5-carboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-76-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-(2-fluoro-3-pyridinyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-81-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[(4-methylphenyl)ethynyl]- (9CI) (CA INDEX NAME)



RN 748182-82-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-(2-pyridinylethynyl)- (9CI) (CA INDEX NAME)





RN 748182-83-4 HCAPLUS
 CN 2-Thiophenecarboxamide, 5-[(4-fluorophenyl)ethynyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 748182-84-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-(3-pyridinylethynyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 07 May 2004
GI

I



II

AB The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones I and compds. related to pyrrolidones I [R1 = H, alkyl, cycloalkyl; R2 = (un)substituted Ph, CH2Ph, cycloalkyl; R3 = (un)substituted pyridyl, pyrimidinyl, pyrazinyl, Ph]. The invention further relates to methods for identifying and using agents, including small mol. chemical compns. that inhibit HIV replication in a cell, as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS. Preparation of the compds. I is described in 28 synthetic examples. Thus, reacting 4-(3-cyclopentylloxy)-4-methoxyphenyl-pyrrolidin-2-one with 3-bromobenzonitrile in the presence of potassium phosphate and trans-1,2-cyclohexanediamine in DMF/dioxane followed by treating a solution of the resulting benzonitrile with 25% NaOH solution, and then with 35% H2O2 afforded II.

ACCESSION NUMBER: 2004:370899 HCAPLUS
DOCUMENT NUMBER: 140:391194
TITLE: Preparation of pyrrolidones with anti-HIV activity
INVENTOR(S): Wu, Baogen; He, Yun; Ngyuen, Truc; Kuhen, Kelli L.; Ellis, David; Archer, Jiang, Tao
PATENT ASSIGNEE(S): IRM LLC, Bermuda
SOURCE: PCT Int. Appl., 201 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

L7 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2004037784 | A2 | 20040506 | WO 2003-US33560 | 20031021 |
| WO 2004037784 | A3 | 20040819 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004157859 | A1 | 20040812 | US 2003-690873 | 20031021 |
| PRIORITY APPLN. INFO.: | | | US 2002-420480P | P 20021021 |
| | | | US 2002-422619P | P 20021030 |

OTHER SOURCE(S): MARPAT 140:391194


IT 686712-45-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-phenylpyrrolidin-2-ones with anti-HIV activity)

RN 686712-45-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-{4-[3-(cyclopentylloxy)-4-methoxyphenyl]-2-oxo-1-pyrrolidinyl}phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 13 Jul 2001
AB Pharmaceutical and veterinary uses of endothelin antagonists are provided. In particular, methods of treatment of laminitis, such as equine and bovine laminitis, by administration of one or more endothelin antagonists are provided. Methods are also provided for the treatment, prevention, or amelioration of one or more symptoms of menopause; osteoporosis and metabolic bone disorders; climacteric disorders, including hot flushes or flashes, abnormal clotting patterns, urogenital discomfort and increased incidence of cardiovascular disease, and other disorders associated with the reduction in ovarian function in women; pre-eclampsia; and control and management of labor during pregnancy by administration of endothelin antagonists.

ACCESSION NUMBER: 2001:507533 HCAPLUS
DOCUMENT NUMBER: 135:102580
TITLE: Pharmaceutical and veterinary uses of endothelin antagonists for treatment of laminitis and other conditions, and preparation thereof
INVENTOR(S): Brock, Thomas A.; Ward, Patrick R.
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2001049289 | A1 | 20010712 | WO 2000-US35280 | 20001227 |
| W: AE, AG, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2001024567 | A5 | 20010716 | AU 2001-24567 | 20001227 |
| PRIORITY APPLN. INFO.: | | | US 1999-174125P | P 19991231 |
| | | | WO 2000-US35280 | W 20001227 |

OTHER SOURCE(S): MARPAT 135:102580

IT 350225-01-3


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(reaction; endothelin antagonists for veterinary or pharmaceutical use in treatment of laminitis and other conditions)

RN 350225-01-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[4-chloro-3-methyl-5-oxazolyloxy]amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]-, monosodium salt (9CI) (CA INDEX NAME)


L7 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Nov 2000
GI



AB REZDR3 [1; D.E = Z1NR5C(X); Z1NR500-2, etc.; R,R3 = (un)substituted heterocyclyl or -aryl; RS = H, (ar)alkyl, aryl; X = O, S, H2; Z = (un)substituted heterocyclylene or -arylene; Z1 = bond, alkylene, alkylidene, etc.] were prepared as factor Xa, thrombin, and prothrombinase inhibitors. Thus, H2NZCONHC6H4Cl-4 (Z = 4-chloro-1,2-phenylene) (preparation given) was N-acylated by 3-chloro-4-chloromethyl-2-thiophenecarbonyl chloride and the product aminated by 1-methylpiperazine to give title compound II. Data for biol. activity of I were given.


ACCESSION NUMBER: 2000:769086 HCAPLUS
DOCUMENT NUMBER: 133:335159
TITLE: Preparation of N-pyridinyl-2-[(thienylcarbonyl)amino]benzamides and analogs as anticoagulants
INVENTOR(S): Arnaiz, Damian O.; Chou, Yuo-ling; Griedel, Brian D.; Karanjawala, Rushad E.; Kochanny, Monica J.; Lee, Wheeseong; Liang, Amy Mei; Morrissey, Michael M.; Phillips, Gary B.; Sacchi, Karna Lynn; Sakata, Steven T.; Shaw, Kenneth J.; Snider, R. Michael; Wu, Shung C.; Ye, Bin; Zhao, Zuchun
PATENT ASSIGNEE(S): Berlex Laboratories, Inc., USA
SOURCE: U.S., 113 pp., Cont.-in-part of U.S. Ser. No. 994,284, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| US 6140351 | A | 20001031 | US 1998-187459 | 19981105 |
| CA 2315070 | AA | 19990701 | CA 1998-2315070 | 19981127 |
| WO 9932477 | A1 | 19990701 | WO 1998-EP7650 | 19981127 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 9918759 | A1 | 19990712 | AU 1999-18759 | 19981127 |
| AU 751856 | B2 | 20020829 | | |

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


EP 1040108 A1 20001004 EP 1998-963519 19981127
EP 1040108 B1 20040225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2001526283 T2 20011218 JP 2000-525414 19981127
NZ 503809 A 20020426 NZ 1998-503809 19981127
AT 260103 E 20040315 AT 1998-963519 19981127
RU 2226529 C2 20040410 RU 2000-119756 19981127
PT 1040108 T 20040630 PT 1998-963519 19981127
ES 2215337 T3 20041001 ES 1998-963519 19981127
ZA 9811599 A 19990817 ZA 1998-11599 19981217
NO 2000003111 A 20000818 NO 2000-3111 20000616
US 6380221 B1 20020430 US 2000-631450 20000803
US 6498185 B1 20021224 US 2000-631452 20000803
US 1997-994284 B2 19971219
US 1998-187459 A 19981105
WO 1998-EP7650 W 19981127

PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 133:335159
IT 229335-18-6P 229337-47-7P 229340-25-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-pyridinyl-2-[(thienylcarbonyl)amino]benzamides and analogs as anticoagulants)
RN 229335-18-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[5-chloro-2-pyridinyl]amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229337-47-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[5-chloro-2-pyridinyl]amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[(2-hydroxyethyl)methylamino]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 229340-25-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[5-chloro-2-pyridinyl]amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[(2-hydroxyethyl)methylamino]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CN 1
CRN 229337-47-7
CMF C25 H26 Cl3 N5 O3 S



CN 2
CRN 76-05-1
CMF C2 H F3 O2

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 05 Oct 1999

AB We have previously disclosed the discovery of 2,4-disubstituted anilinothiophenesulfonamides with potent ETA-selective endothelin receptor antagonism and the subsequent identification of sitaxsentan (TBC1251, 1) as a clin. development compound. The orally active 1 has demonstrated efficacy in a phase II clin. trial of congestive heart failure and was active in rat models of myocardial infarction and acute hypoxia-induced pulmonary hypertension. We now report that an addl. substituent at the 6-position of the anilino ring further increases the potency of this series of comds. It was also found that a wide range of functionalities at the 3-position of the 2,4,6-trisubstituted ring increased ETA selectivity by .apprx.10-fold while maintaining in vitro potency, therefore rendering the comds. amenable to fine-tuning of pharmacol. and toxicol. profiles with enhanced selectivity. The optimal compound in this series was found to be TBC2576, which has .apprx.10-fold higher ETA binding affinity than 1, high ETA/ETB selectivity, and a serum half-life of 7.3 h in rats, as well as in vivo activity.

ACCESSION NUMBER: 1999:628908 HCAPLUS

DOCUMENT NUMBER: 131:346149

TITLE: Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ETA Receptors

AUTHOR(S): Wu, Chengde; Decker, E. Radford; Blok, Natalie; Bui, Huong; Chen, Qi; Raju, B.; Bourgoynne, Andree R.; Knowles, Vipra; Biediger, Ronald J.; Market, Robert V.; Lin, Shuqun; Dupre, Brian; Kogan, Timothy P.; Holland, George W.; Brock, Tommy A.; Dixon, Richard A. F.

CORPORATE SOURCE: Texas Biotechnology Corporation, Houston, TX, 77030, USA

SOURCE: Journal of Medicinal Chemistry (1999), 42(22), 4485-4499

CODEN: JMCHEM; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 205516-14-9P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (synthesis of substituted mesitylcarboxamides with high potency and selectivity for ETA receptors)

RN 205516-14-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[4-(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 08 Jul 1999

GI



AB Title comds. [I: m = 1-3; n = 1-5; B, Q = atoms to form aryl, heterocyclyl rings; D, E = NR5CX; R5NR5CX, NR5Op, etc.; p = 0-2; X = O, S, H2; R1 = H, alkyl, aryl, aralkyl, halo, haloalkyl, cyano, OR5, CO2R5, NR5R6, CONR5R6 (substituted) heterocyclyl, etc.; R2 = H, alkyl, aryl, aralkyl, halo, haloalkyl, cyano, OR5, CO2R5, CONR5R6, etc.; R3 = (substituted) heterocyclyl, aryl; R4 = H, alkyl, halo, haloalkyl, cyano, NO2, OR5, CO2R5, NR5R6, etc.; R5, R6 = H, alkyl, aryl, aralkyl; R8 = alkylene, alkenylene, alkynylene], were prepared. Thus, N-(4-chlorophenyl)-2-[[[4-(4-chloromethyl)-3-chlorothiophen-2-ylcarbonyl]amino]-3-methoxy-5-chlorobenzamide in DMF at 0° was treated with N-methylpiperazine followed by stirring to room temperature to give N-(4-chlorophenyl)-2-[[[4-(4-methylpiperazin-1-yl)methyl]-3-chlorothiophen-2-yl]carbonyl]amino]-3-methoxy-5-chlorobenzamide. Title comds. routinely inhibited Factor Xa with Ki<3 nM. An aerosol formulation is given.

ACCESSION NUMBER: 1999:421679 HCAPLUS

DOCUMENT NUMBER: 131:87925

TITLE: Preparation of heteroarylcarbonylaminobenzamides and related compounds as anticoagulants.

INVENTOR(S): Arnaiz, Damlan O.; Chou, Yuo-Ling; Karanjawala, Rushad E.; Kochanny, Monica J.; Lee, Vheeseong; Liang, Amy Mei; Morrissey, Michael M.; Phillips, Gary B.; Sacchi, Karna Lyn; Sakata, Stephen T.; Shaw, Kenneth J.; Snider, R. Michael; Wu, Shung C.; Ye, Bin; Zhao, Zuchun; Griedel, Brian D.

PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 326 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 9932477 | A1 | 19990701 | WO 1998-EP7650 | 19981127 |
| W: AU, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 6140351 | A | 20000131 | US 1998-187459 | 19981105 |
| CA 2315070 | AA | 19990701 | CA 1998-2315070 | 19981127 |
| AU 9918759 | A1 | 19990712 | AU 1999-18759 | 19981127 |
| AU 751856 | B2 | 20020829 | | |

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 EP 1040108 A1 20001004 EP 1998-963519 19981127
 EP 1040106 B1 20040225
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
 JP 2001526283 T2 20011218 JP 2000-525414 19981127
 NZ 503809 A 20020426 NZ 1998-503809 19981127
 AT 260103 E 20040315 AT 1998-963519 19981127
 RU 2226529 C2 20040410 RU 2000-119756 19981127
 NO 2000003111 A 20000818 NO 2000-3111 20000516
 PRIORITY APPLN. INFO.: US 1997-994284 A 19971219
 US 1998-187459 A 19981105
 WO 1998-EP7650 W 19981127

OTHER SOURCE(S): MARPAT 131:87925
 IT 229335-18-6P 229337-47-7P 229340-25-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heteroarylcarbonylamino benzamides and related compds. as anticoagulants)
 RN 229335-18-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[[[2-hydroxyethyl]methylamino]methyl]- (9CI) (CA INDEX NAME)




RN 229337-47-7 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[[[2-hydroxyethyl]methylamino]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 229340-25-4 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[[5-chloro-2-pyridinyl]amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[[[2-hydroxyethyl]methylamino]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
 CRN 229337-47-7
 CMF C25 H26 Cl3 N5 O3 S



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2

L7 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 15 Apr 1998
 GI



AB R1502MHR [1: R = (un)substituted (hetero)aryl; R1 = R22221; R2 = (un)substituted Ph; Z1 = thiophene-, furan-, pyrrole-2,3- or -3,2-diyl, etc.; Z2 = COCH2, CONH, CO2, CH:CH, CH2O, etc.] were prepared. Thus, 2-methoxycarbonyl-3-thiophenesulfonyl chloride was amidated by 5-amino-4-chloro-3-methylisoxazole and the product converted in 5 steps to title compound II. Data for biol. activity of I were given.

ACCESSION NUMBER: 1998:210751 HCAPLUS
 DOCUMENT NUMBER: 128:270601
 TITLE: Preparation of N-isoxazolythiophenesulfonamides and analogs as endothelin activity modulators
 INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Koyan, Timothy P.; Blok, Natalie; Woodard, Patricia
 PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
 SOURCE: PCT Int. Appl., 172 pp.
 CODEN: F1XK02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 10
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 9813366 | A1 | 19980402 | WO 1997-0517402 | 19970926 |
| W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| RW: | GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| US 5962490 | A | 19991005 | US 1996-721183 | 19960927 |
| CA 2261760 | AA | 19980402 | CA 1997-2261760 | 19970926 |
| CA 2261760 | C | 20050329 | | |
| AU 9745059 | A1 | 19980417 | AU 1997-45059 | 19970926 |
| AU 736269 | B2 | 20010726 | | |
| EP 946552 | A1 | 19991006 | EP 1997-943629 | 19970926 |
| EP 946552 | B1 | 20040707 | | |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| BR 9711550 | A | 20000118 | BR 1997-11550 | 19970926 |
| JP 2000507607 | T2 | 20000620 | JP 1998-515979 | 19970926 |

L7 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NZ 334797 A 20010223 NZ 1997-334797 19970926
AT 270669 E 20040715 AT 1997-943629 19970926
NO 9901388 A 19990527 NO 1999-1388 19990322
AU 9935803 A1 19990916 AU 1999-35803 19990622
AU 726595 B2 20001116
PRIORITY APPLN. INFO.:
US 1996-721183 A 19960927
US 1987-100865 A2 19870925
US 1990-416199 A2 19900515
US 1993-65202 B2 19930520
US 1993-100125 B2 19930730
US 1993-100565 A2 19930730
US 1993-142159 A2 19931021
US 1993-142552 A2 19931021
US 1993-142631 B2 19931021
US 1994-222287 A2 19940405
US 1994-247072 A2 19940520
US 1995-417075 A2 19950404
US 1995-477223 A2 19950606
AU 1996-55367 A 19960404
WO 1996-US4759 A2 19960404
WO 1997-US17402 V 19970926


OTHER SOURCE(S): MARPAT 128:270601

IT 205516-14-99

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolythiophenesulfonamides and analogs as endothelin activity modulators)

RN 205516-14-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[4-chloro-3-methyl-5-isoxazoly]amino]sulfonyl-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]-(9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

• Ngrazier 10781442clmland6

• => s l6
L8 11 L6

=> d ed abs ibib hitstr 1-11

L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 Dec 2005
GI




AB Title compds. I [A = carboxy, carboxy bioisostere; L1 = CH₂, OCH₂, CH₂CH₂, etc.; L2 = CONH, NHCO, SO₂NH, etc.; L3 = (Alk1)m-Zn-(Alk2)p; m, n, p = 0-1; Alk1-2 = alkylene, alkenylene, etc.; Z = O, S, CO, etc.; Ar1 = Ph, 5-6 membered heteroaryl, etc.; Ar2 = 1,3-phenylene, 5-6 membered heteroaryl, etc.; B = ring as defined for Ar2, cycloalkyl, etc.; q = 0-1] are prepared. For instance, 5-bromo-2-[[3-((6-chloropyridin-3-yl)sulfamoyl)benzoyl]amino]benzoic acid (II) is prepared from 3-chlorosulfonfylbenzoic acid, 5-amino-2-chloropyridine and Me 2-amino-5-bromobenzoate. II has an IC₅₀ between 0.5 and 5 μM for the CRTH2 receptor. I are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity.


ACCESSION NUMBER: 2005:1289855 HCAPLUS
DOCUMENT NUMBER: 144:36197
TITLE: Preparation of substituted benzamides as CRTH2 receptor ligands
INVENTOR(S): Ulven, Trond; Frimurer, Thomas; Rist, Oeystein; Kostenis, Evi; Hoegberg, Thomas
PATENT ASSIGNEE(S): TTM Pharma A/S, Den.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|---------------|-----------------|----------|
| WO 2005115374 | A1 | 20051208 | WO 2005-EP5883 | 20050530 |
| V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRIORITY APPLN. INFO.: | | GB 2004-12198 | A 20040529 | |
| | | GB 2004-14195 | A 20040624 | |

L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 870808-10-9P 870808-12-1P 870808-14-3P
870808-15-4P 870808-30-3P, 5-Bromo-2-[[4-((4-bromophenyl)sulfamoyl)-3-methylthiophene-2-yl]carbonyl]amino]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
RN (Preparation of substituted benzamides as CRTH2 receptor ligands)
CN 870808-10-9 HCAPLUS
INDEX NAME NOT YET ASSIGNED




RN 870808-12-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 870808-14-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED


L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 870808-15-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED





RN 870808-30-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ED Entered STN: 04 Mar 2005
 GI




AB The invention relates to a preparation of urotensin II receptor antagonists and CCR-9 antagonists of formula I (wherein: R1, R2, and R3 are independently selected from H, halogen, alkyl, aryl, or CN, etc.; X is CH2, O, or NH, etc.; Y is SO2, C(O), CH2SO2, NHC(O), or NHSO2, etc.; T and V are independently selected from H, (cyclo)alkyl, alkoxy, aryl, or halogen, etc.; R4 is aryl, heterocyclyl, or cycloalkyl). For instance, thiophenecarboxamide derivative II was prepared via amidation of thiophene-2-carboxylic acid by [2,4,6-trimethyl-3-(pyrrolidin-1-yl)phenyl]amine. The invention compds. were tested for inhibition of human urotensin II-induced Ca2+ mobilization in UTR cells (IC50 > 0.5 μM).


ACCESSION NUMBER: 2005:185392 HCAPLUS
 DOCUMENT NUMBER: 142:280229
 TITLE: A preparation of urotensin II receptor antagonists and CCR-9 antagonists
 INVENTOR(S): Wu, Chengde; Anderson, C. Eric; Bui, Huong; Gao, Daxin; Kassir, Jamal; Li, Wen; Wang, Junmei; Biediger, Ronald; Chen, Jie; Market, Robert V.
 SOURCE: USA
 PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 781,442.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|-------|-----------------|-------|
| ----- | ---- | ----- | ----- | ----- |


L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethylphenyl]- (9CI) (CA INDEX NAME)




RN 847414-21-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethylphenyl]- (9CI) (CA INDEX NAME)



RN 847414-22-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(methoxymethyl)(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-24-8 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 US 2005049286 A1 20050303 US 2004-924180 20040823
 US 2004180892 A1 20040916 US 2004-781442 20040218
 PRIORITY APPLN. INFO.: US 2003-448791P P 20030220
 US 2004-781442 A2 20040218

OTHER SOURCE(S): MARPAT 142:280229
 IT 749268-37-9P 749268-38-0P 847414-20-4P
 847414-21-5P 847414-22-6P 847414-24-8P
 847414-26-0P 847414-27-1P 847414-30-6P
 847414-31-7P 847414-33-9P 847414-34-0P
 847414-35-1P 847414-36-2P 847414-37-3P
 847414-38-4P 847414-39-5P 847414-40-6P
 847414-41-9P 847414-42-0P 847414-43-1P
 847414-44-2P 847414-45-3P 847414-46-4P
 847414-47-5P 847414-48-6P 847414-49-7P
 847414-50-0P 847414-51-1P 847414-52-2P
 847414-53-3P 847414-56-6P 847414-57-7P
 847414-58-8P 847414-59-9P 847414-60-2P
 847414-61-3P 847414-62-4P 847414-63-5P
 847414-64-6P 847414-65-7P 847414-67-9P
 847414-70-4P 847414-71-5P 847414-72-6P
 847414-73-7P 847414-74-8P 847414-75-9P
 847414-77-1P 847414-80-6P 847414-82-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 RN 749268-37-9 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 749268-37-9 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-20-4 HCAPLUS

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 847414-26-0 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-27-1 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-30-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[3-(3-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-31-7 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[2-(2-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-33-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-methoxyphenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-34-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-methylphenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-35-1 HCAPLUS


L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-38-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-39-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-40-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, 3-[[[4-methylphenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-36-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-methoxyphenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-37-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-chlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-41-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-42-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-chlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-43-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-chlorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-44-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethoxy)phenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-45-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethoxy)phenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847414-48-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(3,5-dichlorophenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-49-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(3,5-difluorophenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-50-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(3,4-dichlorophenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-46-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(4-fluorophenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-47-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(bromophenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 847414-51-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(3,4-difluorophenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 847414-52-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 847414-53-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3,4,5-trifluorophenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-56-6 HCAPLUS
 CN 3-Thiophenecarboxamide, 2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-57-7 HCAPLUS
 CN 3-Thiophenecarboxamide, 4-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-58-8 HCAPLUS
 CN 3-Thiophenecarboxamide, 4,5-dimethyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Thiophenecarboxamide, 3-[[[2-fluorophenyl]amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-63-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[4-fluorophenyl]amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-64-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[3-fluorophenyl]amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 847414-65-7 HCAPLUS


L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847414-59-9 HCAPLUS
 CN 3-Thiophenecarboxamide, 4-methyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-60-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[2,6-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-61-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[2,4-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-62-4 HCAPLUS


L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Thiophenecarboxamide, N-[3-bromo-2,4,6-trimethylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-67-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-70-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-cyclopropyl-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 847414-71-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[[[4-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-72-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 847414-73-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethyl[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 847414-74-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 847414-82-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[methyl(phenylsulfonyl)amino]-N-(2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl)- (9CI) (CA INDEX NAME)




L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-75-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,2',4,6,6'-pentamethyl[1,1'-biphenyl]-3-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)





RN 847414-77-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(diethylamino)-2,4,6-trimethylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-80-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-methoxy-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Sep 2006
GI




AB The title compds. I and II [R1, R2, R3 = H, halo, alkyl, aryl, aralkyl, CN, CF3, etc.; X = N, CH2, or O; Y = SO2, CO, CH2SO2, CH2CO, NHCO, OCO, or NHSO2; R4 = alkyl, aralkyl or (hetero)aryl, R5 = R1, or Z-NR7R8, or R4, R5 taken together with N can form a 5 or 6 membered ring; Z = (CH2)n, where n = 0-6; R6 = (hetero)aryl, Z-NR7R8; R7, R8 = H, alkyl, aryl, aralkyl or together with N form a pyrrolidine, piperazine, piperidine, or morpholine ring; E = substituted amino, O, S, CR13=CR14, or CR13=N, where R13, R14 = alkyl, (hetero)aryl, halo, OH, alkoxy, etc.; D = substituted amino, O, or S; Z = NR15 or CR15R16 where each R15 = H, alkyl, aryl, or heteroaryl; A = (substituted)amino, CO, or SO2; when A = (substituted)amino, B = SO2, CO2, or C16R16, where R16 = H, alkyl, aryl, or heteroaryl; when A = CO or SO2, B = (substituted)amino; R9, R10 = H, alkyl, (hetero)aryl, halo, OH, Alkoxy, or (substituted)amino; R11, R12 = H, alkyl, or (hetero)aryl] were prepared as uterostensin-II receptor antagonists and CCR-9 antagonists for the treatment of congestive heart failure, stroke, ischemic heart disease, etc. For example, reaction of 2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylamine (preparation given) with 1-naphthalenesulfonyl chloride yielded compound III. The latter showed an IC50 = 10 μM in the assay of human uterostensin-II-induced CA2+ mobilization in UTR cells.

ACCESSION NUMBER: 2004:718308 HCAPLUS
DOCUMENT NUMBER: 141:243188
TITLE: Preparation of phenylenediamine and thiophene carboxylic amide derivatives as uterostensin-II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, Eric C.; Bui, Huong; Gao, Dawin; Kassir, Jamal; Li, Wen; Wang, Junmei; Macket, Robert V.
PATENT ASSIGNEE(S): Encysive Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2


L8 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2004073634 | A2 | 20040902 | WO 2004-US4645 | 20040218 |
| V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2515780 | AA | 20040902 | CA 2004-2515780 | 20040218 |
| EP 1610753 | A2 | 20060104 | EP 2004-712313 | 20040218 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| PRIORITY APPLN. INFO.: US 2003-448791P P 20030220 WO 2004-US4645 W 20040218 | | | | |

OTHER SOURCE(S): MARPAT 141:243188
 IT 749268-37-9P, 3-Phenylaminosulfonyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide 749268-38-0P, 3-Benzenesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of phenylenediamine and thiophene carboxylic amide derivs. as uterensin-II receptor antagonists and CCR-9 antagonists)
 RN 749268-37-9 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 05 Mar 2004
GI

AB The title compds. I [X = NH; Y = CO, CS, C=NCN, or X and Y together form an alkene, or cycloalkyl; R1 = (un)substituted-heterocycle, -heterocyclylcarbonyl, NHSO2R3; R2 = electron withdrawing group; R3 = H, (un)substituted alkyl or aryl; R4 = (un)substituted aryl with provisions] and their pharmaceutically acceptable salts are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared by amidation of 3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl chloride (preparation given) with 3-(2-amino-5-bromophenyl)-1,2,4-oxadiazol-5(4H)-one. In assays, the min. inhibitory concentration values (µg/mL) ranged from 0.125 - >128. As antibacterial agents I are useful for sterilization, sanitation, antiseptics, and disinfection.


ACCESSION NUMBER: 2004:182873 HCAPLUS
 DOCUMENT NUMBER: 140:235499
 TITLE: Preparation of aminoarylbenzoic acid derivatives as antibacterial agents for use as disinfectants and therapeutic agents
 INVENTOR(S): Thorarensen, Atli; Ruble, Craig J.; Romero, Donna L.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 167 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: L

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2004018461 | A2 | 20040304 | WO 2003-US24791 | 20030820 |
| WO 2004018461 | A3 | 20040826 | | |
| V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OA, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |


L8 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 749268-61-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of phenylenediamine and thiophene carboxylic amide derivs. as uterensin-II receptor antagonists and CCR-9 antagonists)
 RN 749268-61-9 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(methoxymethyl)phenylamino)sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 2004142981 A1 20040722 US 2003-645799 20030820
PRIORITY APPLN. INFO.: US 2002-405614P P 20020823
US 2002-413596P P 20020925
US 2002-430351P P 20021202

OTHER SOURCE(S): MARPAT 140:235499
 IT 666859-72-9P 666859-73-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)
 RN 666859-72-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-bromo-2-cyanophenyl)-5-[[4-(4-chlorophenyl)methylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 666859-73-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-bromo-2-cyanophenyl)-5-[[4-(4-chlorophenyl)methylamino)sulfonyl]- (9CI) (CA INDEX NAME)




IT 666859-26-3P 666859-28-5P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)
 RN 666859-26-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-bromo-2-(1H-tetrazol-5-yl)phenyl]-4-[[4-(4-chlorophenyl)methylamino)sulfonyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 66859-28-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[(4-bromo-2-(1H-tetrazol-5-yl)phenyl)-5-[[[(4-chlorophenyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 05 Mar 2004
 GI



AB Title compds. I [X = NH; Y = CO, CS, C(NCN), or X and Y together form an alkene or cycloalkyl; R1 = CO2H; R2 = electron withdrawing group; R4 = (un)substituted heterocycle, provided that the heterocycle is not simultaneously substituted with a sulfonamide and a urea or thiourea] and their pharmaceutically acceptable salts are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared via conversion of 7-(benzyloxy)-1-methyl-1H-indole-2-carboxylic acid (preparation given) to the acid chloride which is reacted with tert-butyl-2-amino-5-cyanobenzoate then subjected to hydrolysis. For compds. of the invention, the min. inhibitory concentration was determined and found to correspond to a range of 0.0075


>128 µg/mL. The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antiseptics, disinfection, and treatment of infections in mammals.
 ACCESSION NUMBER: 2004:182843 HCAPLUS
 DOCUMENT NUMBER: 140:235498
 TITLE: Preparation of antibacterial benzoic acid derivatives
 INVENTOR(S): Thorarensen, Atli; Ruble, Craig J.; Fisher, Jed F.; Romero, Donna L.; Beauchamp, Thomas J.; Northuis, Jill M.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 500 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2004018428 | A1 | 20040304 | WO 2003-US24796 | 20030822 |
| V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RV: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, | | | | |


L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2004110802 A1 20040610 US 2003-645802 20030820
 PRIORITY APPLN. INFO.: US 2002-405429P P 20020823
 US 2002-430592P P 20021203

OTHER SOURCE(S): MARPAT 140:235498
 IT 668975-53-9P 668975-55-1P 668975-56-2P
 668975-57-3P 668975-58-4P 668975-59-5P
 668975-60-6P 668975-61-7P 668975-62-8P
 668975-63-9P 668975-64-0P 668975-65-1P
 668975-66-2P 668975-67-3P 668975-68-4P
 668975-69-5P 668975-70-6P 668975-71-7P
 668975-72-8P 668975-73-9P 668975-74-0P
 668975-75-1P 668975-76-2P 668975-77-3P
 668975-78-4P 668975-79-5P 668975-80-6P
 668975-81-7P 668975-82-8P 668975-83-9P
 668975-84-0P 668975-85-1P 668975-86-2P
 668975-87-3P 668975-88-4P 668975-89-5P
 668975-90-6P 668975-91-7P 668975-92-8P
 668975-93-9P 668975-94-0P 668975-95-1P
 668975-96-2P 668975-97-3P 668975-98-4P
 668975-99-5P 668975-100-6P

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzoic acid derivs. as antibacterial agents)
 RN 668975-53-9 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[5-[[[(4-chlorophenyl)methylamino]sulfonyl]-3-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668975-55-1 HCAPLUS
 CN Benzoic acid, 2-[[[5-[[[(1,3-benzodioxol-5-ylamino)sulfonyl]-3-thienyl]carbonyl]amino]-5-bromo- (9CI) (CA INDEX NAME)




RN 668975-56-2 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[(2,3-dihydro-1,4-benzodioxin-6-


L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 yl)amino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668975-57-3 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[(3-chloro-4-fluorophenyl)amino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668975-58-4 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[3-methyl-4-[[[(4-morpholinyl)phenyl]amino]sulfonyl]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668975-59-5 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[(diethylamino)phenyl]amino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 668975-86-8 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[3-chloro-4-fluorophenyl]amino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668975-87-9 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[2,3-dihydro-1,4-benzodioxin-6-yl]amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 668975-91-5 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[2,3-dihydro-1,4-benzodioxin-6-yl]amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668976-56-5 HCAPLUS
 CN Benzoic acid, 5-cyano-2-[[[4-[[[2,3-dihydro-1H-inden-5-yl]amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668979-22-4 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[4-chlorophenyl]methylamino]sulfonyl]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 668975-88-0 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[4-chlorophenyl]amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668975-89-1 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[5-[[[4-(diethylamino)phenyl]amino]sulfonyl]-3-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 668979-23-5 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[5-[[[4-chlorophenyl]methylamino]sulfonyl]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668979-26-8 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[4-chlorophenyl]methylamino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 668979-27-9 HCAPLUS
 CN Benzoic acid, 5-bromo-2-[[[4-[[[4-chlorophenyl]methylamino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 668979-31-5 HCAPLUS

CN Benzoic acid, 5-bromo-2-[[[5-methyl-4-[(2-methyl-5-benzothiazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 05 Jan 2003
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Inks containing phthalocyanine compds. I [X1-X4 = SO₂, SO₂Z; Z = (un)substituted (cyclo)alkyl, alkenyl, aryl, etc.; Y1-Y4 = H, halo, (cyclo)alkyl, amino, etc.; M = H, metal or oxide, hydroxide, and halide thereof; a1-a4 = 0-4 with the proviso that a1-a4 are not simultaneously 0; b1-b4 = 0-4; I1 [R1-R8 = H, halo, (cyclo)alkyl, amino, etc.; R11-R18 = H, halo, substituted sulfamoyl], and I11 [R1-R8 = H, halo, (cyclo)alkyl, amino, etc.; Z1-Z4 = (un)substituted heterocyclic group; l, m, n, p = 1, 2; Y1-Y4 = necessary atom group for formation of (fused) heterocyclic rings; l, m, n, p = 1, 2], as a primary colorant have excellent color reproducibility and sufficient fastness against light, heat, moisture, and active gases in the surroundings. Thus, the inks can provide colored images and colored materials being excellent in color hue and fastness. They are usable in jet printing ink compns., ink sheets for use in thermal transfer image-forming materials, electrophotog. toners, various coloring compns. for color filters for use in LCD, PDP and CCD, and liquid dyes for various fibers, etc.

ACCESSION NUMBER: 2003:6064 HCAPLUS

DOCUMENT NUMBER: 138:74847

TITLE: Colored image-forming compositions containing phthalocyanine compounds, inks, ink-jet inks, ink-jet recording method and method of improving tolerance to decoloration due to ozone gas

INVENTOR(S): Tateishi, Keiichi; Noro, Masaki; Yabuki, Yoshiharu;

ONATSU, Tadashi

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: PCT Int. Appl., 230 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2003000811 | A1 | 20030103 | WO 2002-JP6248 | 20020621 |
| W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, D2, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| JP 2003003109 | A2 | 20030108 | JP 2001-189982 | 20010622 |
| JP 2003003099 | A2 | 20030108 | JP 2001-190215 | 20010622 |
| JP 2003003086 | A2 | 20030108 | JP 2001-190216 | 20010622 |
| CA 2422030 | AA | 20030310 | CA 2002-2422030 | 20020621 |
| EP 1408093 | A1 | 20040414 | EP 2002-741247 | 20020621 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

L8 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003119415 A2 20030423 JP 2002-183156 20020624
US 2004099181 A1 20040527 US 2003-362140 20031031
PRIORITY APPLN. INFO.: JP 2001-189982 A 20010622
JP 2001-190214 A 20010622
JP 2001-190215 A 20010622
JP 2001-190216 A 20010622
WO 2002-JP6248 W 20020621

OTHER SOURCE(S): MARPAT 138:74847


IT 480428-37-3

RI: TEM (Technical or engineered material use); USES (Uses)
(phthalocyanine colorants for toners with excellent color hue and fastness)

RN 480428-37-3 HCAPLUS


CN Cuprate(4-), [[2,2',2'',2'''-[(29H,31H-phthalocyanine-2,9,16,23-tetrayl-
-N29,N30,N31,N32)tetrakis(sulfonylimino)]tetrakis
is[4-methyl-5-[[[3-[[[1-methylethyl]amino]sulfonyl]phenyl]amino]carbonyl]-
3-thiophenecarboxylato]](6-)]-, tetrahydrogen, (SP-4-1)- (9CI) (CA INDEX NAME)

PAGE 1-B







L8 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




PAGE 2-B



● 4 H⁺

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB The title compds. [I-III; X = S, O; R¹ = H, alkyl, aryl, etc.; R², R³ = alkyl, haloalkyl, alky, interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared. E.g., a 4-step synthesis of I [X = S; R¹ = H; R² = 4-FC₆H₄; R³ = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

ACCESSION NUMBER: 2002:275753 HCAPLUS
 DOCUMENT NUMBER: 136:309843
 TITLE: Preparation of thiophenes as phosphate transport inhibitors
 INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 66 pp.
 COHEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2002028353 | A2 | 20020411 | WO 2001-US31318 | 20011005 |
| WO 2002028353 | A3 | 20020711 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002013048 A5 20020415 AU 2002-13048 20011005


OTHER SOURCE(S): MARPAT 136:309843

IT 409361-90-6P 409361-91-7P 409361-92-8P
 409361-93-9P 409361-94-0P 409361-95-5P
 409362-00-1P 409362-01-2P 409362-02-3P
 409362-03-4P 409362-04-5P 409362-05-6P
 409362-06-7P 409362-11-4P 409362-12-5P
 409362-13-6P 409362-14-7P 409362-17-0P
 409362-18-1P 409362-19-2P 409362-20-5P
 409362-22-7P 409362-28-3P 409362-29-4P
 409362-30-7P 409362-31-8P 409362-32-9P
 409362-33-0P 409362-34-1P 409362-35-2P
 409362-36-3P 409362-37-4P 409362-38-5P
 409362-39-6P 409362-40-9P 409362-41-0P
 409362-42-1P 409362-43-2P 409362-44-3P
 409362-45-4P 409362-46-5P 409362-47-6P
 409362-48-7P 409362-49-8P 409362-50-1P
 409362-51-2P 409362-52-3P 409362-53-4P
 409362-54-5P 409362-55-6P 409362-56-7P
 409362-57-8P 409362-58-9P 409362-59-0P
 409362-60-3P 409362-61-4P 409362-62-5P
 409362-63-6P 409362-64-7P 409362-65-8P
 409362-66-9P 409362-67-0P 409362-68-1P
 409362-69-2P 409362-70-5P 409362-71-6P
 409362-72-7P 409362-73-8P 409362-75-0P
 409362-76-1P 409362-77-2P 409362-78-3P
 409362-81-8P 409362-82-9P 409362-83-0P
 409362-84-1P 409362-85-2P 409362-87-4P
 409362-93-2P 409362-95-4P 409362-97-6P
 409362-98-7P 409363-00-4P 409363-01-5P
 409363-02-6P 409363-03-7P 409363-04-8P
 409363-05-9P 409363-06-0P 409363-07-1P
 409363-08-2P 409363-10-6P 409363-15-1P
 409363-17-3P 409363-19-5P 409363-21-9P
 409363-25-3P 409363-27-5P 409363-28-6P
 409363-29-7P 409363-30-0P 409363-31-1P
 409363-32-2P 409363-35-5P 409363-36-6P
 409363-41-3P 409363-51-5P 409363-52-6P
 409363-53-7P 409363-54-8P 409363-57-1P
 409363-58-2P 409363-59-3P 409363-60-6P
 409363-61-7P 409363-62-0P 409363-63-9P
 409363-64-0P 409363-65-1P 409363-66-2P
 409363-67-3P 409363-69-5P 409363-70-8P
 409363-71-9P 409363-72-0P 409363-73-1P
 409363-74-2P 409363-75-3P 409363-76-4P
 409363-77-5P 409363-78-6P 409363-79-7P
 409363-80-0P 409363-81-1P 409363-82-2P
 409363-83-3P 409363-84-4P 409363-85-5P
 409363-86-6P 409363-87-7P 409363-88-8P
 409363-89-9P 409363-90-2P 409363-91-3P
 409363-92-4P 409363-93-5P 409363-94-6P
 409363-95-7P 409363-96-8P 409363-97-9P
 409363-98-0P 409363-99-1P 409364-00-7P
 409364-01-8P 409364-02-9P 409364-03-0P
 409364-04-1P 409364-05-2P 409364-06-3P
 409364-29-0P 409364-31-4P 409364-33-6P
 409364-35-8P 409364-37-0P 409364-39-2P
 409364-41-6P 409364-43-8P 409364-45-0P
 409364-47-2P 409364-49-4P 409364-51-8P
 409364-53-0P 409364-54-1P 409364-56-3P
 409364-64-3P 409364-65-4P 409364-66-5P

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 409364-67-6P 409364-68-7P 409364-69-8P
 409364-70-1P 409364-71-2P 409364-72-3P
 409364-73-4P 409364-81-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of thiophenes as phosphate transport inhibitors)
 RN 409361-90-6 HCAPLUS
 CN 3-Thiophenecarboxamide, N-(3-chlorophenyl)-4-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409361-91-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409361-92-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[2-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-00-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-01-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[2-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-02-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[2-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409361-93-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[4-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409361-94-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409361-99-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-03-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[4-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-04-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[4-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-05-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-06-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-11-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-12-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[2-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-18-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[2-fluorophenyl]sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-19-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[4-methoxyphenyl]sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 409362-20-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[4-methoxyphenyl]sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-13-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-14-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-17-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(trifluoromethyl)phenyl]-3-[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409362-22-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-28-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-29-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-methylethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 409362-30-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-phenoxyphenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)



RN 409362-31-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-(hexyloxy)phenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409362-32-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-methoxyphenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409362-33-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(1-methylethoxy)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 409362-37-4 HCAPLUS
 CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
 butyl ester (9CI) (CA INDEX NAME)




RN 409362-38-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(1-oxopropyl)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-39-6 HCAPLUS
 CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
 ethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-34-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-acetylphenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409362-35-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-benzoylphenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409362-36-3 HCAPLUS
 CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
 ethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 409362-40-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(2-hydroxyethyl)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-41-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-42-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(diethylamino)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-43-2 HCAPLUS
 CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 409362-44-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 409362-45-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[(1H-indazol-6-ylamino)sulfonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-46-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 409362-47-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(hydroxymethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-52-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-phenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-53-4 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 409362-54-5 HCAPLUS
 CN Benzoic acid, 2-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409362-48-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-cyclohexylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-49-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-50-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-51-2 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 409362-55-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-56-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(2,6-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-57-8 HCAPLUS
 CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409362-58-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-59-0 HCAPLUS


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Thiophenecarboxamide, N-1,3-benzodioxol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-60-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-61-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-62-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(2-benzoyl-4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409362-66-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-9H-fluoren-2-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-67-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[(phenylamino)carbonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-68-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-69-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-2-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-63-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(1H-indol-2-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-64-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-5-isoquinolinyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-65-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-2-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409362-70-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-71-6 HCAPLUS
 CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 409362-72-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-73-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,4-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409362-75-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409362-76-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-acetylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-77-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409362-84-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(1H-pyrrol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-85-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-87-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-93-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-ethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 409362-78-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-6-quinoliny- (9CI) (CA INDEX NAME)



RN 409362-81-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-82-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409362-83-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409362-95-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-97-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-98-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-00-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-01-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(1H-benzotriazol-5-yl-3-[(phenylsulfonyl)amino]-2-thienylcarbonylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 409363-02-6 HCAPLUS
CN Benzoic acid, 2-methoxy-5-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonylamino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409363-03-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methyl-6-benzothiazolyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-08-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-5-quinoliny- (9CI) (CA INDEX NAME)




RN 409363-10-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-15-1 HCAPLUS
CN Benzoic acid, 4-methoxy-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonylamino]-, methyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409363-04-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(1,3-dihydro-5-isobenzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-05-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-[(1-methyl-1H-pyrazol-3-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-06-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-[(2-methyl-4-pyrimidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-07-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-[(5-oxazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-17-3 HCAPLUS
CN Benzoic acid, 4-methyl-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonylamino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409363-19-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-[(phenylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-21-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-8-quinoliny- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409363-25-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 409363-27-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-28-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409363-35-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(4-(trifluoromethyl)sulfonyl)phenyl)- (9CI) (CA INDEX NAME)



RN 409363-36-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409363-41-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-51-5 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 409363-29-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-30-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(dimethylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-31-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-32-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN 2-Thiophenecarboxamide, N-[2-(phenylmethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-52-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-3-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-53-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(4-chlorophenoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-54-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(methylthio)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-57-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-1-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-58-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[[2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-59-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-4-methyl-3-[[phenylsulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-60-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(2,3-dihydro-5-benzofuranyl)-3-[[phenylsulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-64-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-65-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[3-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-66-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-61-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(2-chloro-3-methylphenyl)-3-[[phenylsulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-62-8 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409363-63-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3-(trifluoromethyl)phenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-67-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-69-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-70-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3-(trifluoromethyl)phenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409363-71-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-72-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-(difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-76-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[3-bis(trifluoromethyl)phenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-77-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[3-chloro-4-fluorophenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-78-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3-fluoro-2-methylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409363-73-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[4-chloro-3,5-dimethylphenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-74-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[4-bromophenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-75-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-79-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,5-dichlorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-80-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[3-chloro-2-methylphenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-81-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,4-dichlorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-82-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[3,5-difluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-83-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2-chloro-4-fluorophenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-84-4 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409363-87-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2,4-dichlorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-88-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-nitrophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-89-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-acetylphenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, 3-[[[2-bromophenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-85-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2,6-dichlorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-86-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-iodophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-90-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2-chloro-4-cyanophenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-91-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-cyanophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-92-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409363-93-5 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,5-dichloro-4-hydroxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-94-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,5-dimethoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-98-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-methylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-99-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-methylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-00-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-ethylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409363-95-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-96-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-methoxy-5-methylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-97-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,5-difluoro-4-methoxyphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-01-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-methylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-02-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-ethylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-03-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,4,6-trimethylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-04-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(2-methyl-1-naphthyl)sulfonyl]amino- (9CI) (CA INDEX NAME)




RN 409364-05-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(1-naphthyl)sulfonyl]amino- (9CI) (CA INDEX NAME)




RN 409364-06-3 HCAPLUS


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-33-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-fluorophenyl)-3-[(3,4-difluorophenyl)sulfonyl]amino-N-(3-(trifluoromethoxy)phenyl)- (9CI) (CA INDEX NAME)




RN 409364-35-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-fluorophenyl)-3-[(3,4-difluorophenyl)sulfonyl]amino-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 409364-37-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[(3,4-difluorophenyl)sulfonyl]amino- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-29-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[[[3-(4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 409364-31-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[[[3-(4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-39-2 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[[[3-(4-difluorophenyl)sulfonyl]amino]-N-(4-(hexyloxy)phenyl)- (9CI) (CA INDEX NAME)




RN 409364-41-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[[[3-(4-difluorophenyl)sulfonyl]amino]-N-(4-butoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-43-8 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-45-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-47-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[(3,4-difluorophenyl)sulfonyl]amino]-N-(2-methylthio)phenyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-53-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[(3,4-difluorophenyl)sulfonyl]amino]-N-phenyl]- (9CI) (CA INDEX NAME)




RN 409364-54-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-56-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 409364-49-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[(3,4-difluorophenyl)sulfonyl]amino]-N-(4-phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-51-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-64-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-5-(4-fluorophenyl)-3-[[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-65-4 HCAPLUS
CN [2,2'-Bithiophene]-5-carboxamide, N-(3-chlorophenyl)-4-[[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-66-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[(4-chlorophenyl)sulfonyl]amino]-4-methyl- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-67-6 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)




RN 409364-68-7 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3,5-difluorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)




RN 409364-69-8 HCAPLUS


L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3-Thiophenecarboxamide, 4-[[3,4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)-(9CI) (CA INDEX NAME)




RN 409364-73-4 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-2-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)




RN 409364-81-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)




L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409364-70-1 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-fluorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)




RN 409364-71-2 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3-fluorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409364-72-3 HCAPLUS

L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 23 Jan 2000
GI



AB The title compds. [I; A1 = (un)substituted phenylene, naphthylene, heteroarylene; ring A2 comprises the carbon atoms which carry the groups C(X)NH and NHSO2R2 is a benzene, naphthalene, (un)saturated 3-7 membered carbocycle, etc.; R1 = (un)substituted aryl, heterocyclyl, C1-18 alkyl; R2 = (un)substituted aryl, heterocyclyl, C1-10 alkyl, etc.; R3 = H, halo, CF3, etc.; n = 0-2; X = O, NH], useful for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis, were prepared. The compds. I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. Thus, reacting 4-[(2-(4-chlorophenylsulfonyl)-4,5-dimethoxybenzoyl)amino]benzenesulfonyl fluoride (preparation given) with thiomorpholine afforded 65% II which showed 34.8-fold stimulation ((cGMP) test substance/(cGMP) control) at 50 µM.

ACCESSION NUMBER: 2000:53572 HCAPLUS
DOCUMENT NUMBER: 132:93104
TITLE: Preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production
INVENTOR(S): Schindler, Ursula; Schonafinger, Karl; Strobel, Hartmut
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 200002851 | A1 | 20000120 | WO 1999-EP4426 | 19990625 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW | | | | |

L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|-------------|----|----------|------------------|----------|
| DE 19830430 | A1 | 20000113 | DE 1998-19830430 | 19980708 |
| DE 19903126 | A1 | 20000803 | DE 1999-19903126 | 19990127 |
| CA 2336807 | AA | 20000120 | CA 1999-2336807 | 19990625 |
| AU 9946160 | A1 | 20000201 | AU 1999-46160 | 19990625 |
| AU 761983 | B2 | 20030612 | | |
| BR 9911914 | A | 20010327 | BR 1999-11914 | 19990625 |
| EP 1095016 | A1 | 20010502 | EP 1999-929318 | 19990625 |
| EP 1095016 | B1 | 20051109 | | |


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, PT, IE, FI
 JP 2002520309 T2 20020709 JP 2000-559082 19990625
 RU 2234497 C2 20040820 RU 2001-103645 19990625
 AT 309206 E 20051115 AT 1999-929318 19990625
 NO 2001000013 A 20010301 NO 2001-13 20010102
 DE 1998-19830430 A 19980708
 DE 1999-19903126 A 19990127
 WO 1999-EP4426 W 19990625

OTHER SOURCE(S): MARPAT 132:93104
 IT 254877-23-1P 254877-27-5P 254878-40-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of sulfur substituted sulfonylaminocarboxylic acid N-acylamides as modulators of cyclic guanosine monophosphate (cGMP) production)
 RN 254877-23-1 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254877-27-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 13 Jan 2000
 GI



AB Title compds. [1; A1 = (substituted) phenylene, naphthylene, heteroarylene; A2 = atoms to form Ph, naphthyl, carbocyclyl, heterocyclyl rings; R1 = (substituted) aryl, heterocyclyl, alkyl; R2 = R1, amino; R3 = 21 of H, halo, CF3, OH, alkoxy, alkonyalkoxy, aryloxy, NO2, cyano, amino, CO2H, etc.; X = O, NH, etc.; n = 0-2], were prepared. Thus, 4-[[2-(4-chlorophenyl)sulfonyl]amino]-4,5-dimethoxybenzoyl]benzenesulfonyl fluoride was heated in thiomorpholine at 90° for 30 min. to give 65% 2-(4-chlorophenyl)sulfonyl]amino)-4,5-dimethoxy-N-[4-(thiomorpholin-4-sulfonyl)phenyl]benzamide. The latter at 50 µM gave 34.8-fold stimulation of soluble guanylate cyclase.

ACCESSION NUMBER: 2000:11524 HCAPLUS
 DOCUMENT NUMBER: 132:93102
 TITLE: Preparation of arylsulfonylaminocarboxylic acid N-acylamides as guanylate cyclase activators.
 INVENTOR(S): Schindler, Ursula; Schoenafinger, Karl; Strobel, Hartmut
 PATENT ASSIGNER(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
 SOURCE: Ger. Offen., 24 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------------|------|----------|------------------|----------|
| DE 19830430 | A1 | 20000113 | DE 1998-19830430 | 19980708 |
| CA 2336807 | AA | 20000120 | CA 1999-2336807 | 19990625 |
| WO 200002851 | A1 | 20000120 | WO 1999-EP4426 | 19990625 |


V: AZ, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


| | | | | |
|------------|----|----------|----------------|----------|
| AU 9946160 | A1 | 20000201 | AU 1999-46160 | 19990625 |
| AU 761983 | B2 | 20030612 | | |
| BR 9911914 | A | 20010327 | BR 1999-11914 | 19990625 |
| EP 1095016 | A1 | 20010502 | EP 1999-929318 | 19990625 |
| EP 1095016 | B1 | 20051109 | | |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, PT, IE, FI
 TR 200100147 T2 20010521 TR 2001-200100147 19990625
 JP 2002520309 T2 20020709 JP 2000-559082 19990625
 RU 2234497 C2 20040820 RU 2001-103645 19990625
 AT 309206 E 20051115 AT 1999-929318 19990625
 US 6335334 B1 20020101 US 1999-349933 19990708
 ZA 2000007486 A 20020104 ZA 2000-7486 20001214

L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 254878-40-5 HCAPLUS
 CN Benzenesulfonyl fluoride, 4-[[[3-[[[(4-chlorophenyl)sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 NO 2001000013 A 20010301 NO 2001-13 20010102
 US 2002061887 A1 20020523 US 2001-994730 20011128
 US 6881735 B2 20050419
 US 2004186145 A1 20040923 US 2004-816143 20040402
 DE 1998-19830430 A 19980708
 DE 1999-19903126 A 19990127
 WO 1999-EP4426 W 19990625
 US 1999-349933 A3 19990708
 US 2001-994730 A3 20011128

OTHER SOURCE(S): MARPAT 132:93102
 IT 254877-23-1P 254877-27-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylsulfonylaminocarboxylic acid N-acylamides as guanylate cyclase activators)
 RN 254877-23-1 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 254877-27-5 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




IT 254878-40-5P

L8 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of arylsulfonylaminoarylamides as guanylate cyclase activators)
 RN 254878-40-5 HCAPLUS
 CN Benzenesulfonyl fluoride, 4-[[[3-[[[4-chlorophenyl]sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 03 Aug 1998
 GI



AB The title compds. [I: XA = N-containing heterocyclyl; Y = CONH, (CH2)m, etc.; m = 2, 3; n = 0, 1; Z = 1,4-Ph, N-containing heterocyclyl] are prepared I are useful as fibrinogen receptor antagonists and inhibitors of the aggregation of blood platelets in a mammal (no data). Thus, compound (II; W = BOC, Q = Me) (preparation given) was treated with 1N NaOH and then treated with TFA to give the title compound II (W = Q = H).

ACCESSION NUMBER: 1998:479027 HCAPLUS
 DOCUMENT NUMBER: 129:122673
 TITLE: Fibrinogen receptor antagonists
 INVENTOR(S): Wai, John; Fisher, Thorsten E.; Duggan, Mark E.; Hartman, George D.; Perkins, James J.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: U.S., 37 pp
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|-------------------|-----------------|----------|
| US 5780480 | A | 19980714 | US 1997-807843 | 19970226 |
| PRIORITY APPLN. INFO.: | | | US 1997-807843 | 19970226 |
| OTHER SOURCE(S): | | MARPAT 129:122673 | | |


IT 210347-33-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzene derivs. as fibrinogen receptor antagonists)

RN 210347-33-4 HCAPLUS
 CN Glycine, N-(phenylsulfonyl)-N-[5-[[[4-(1-piperazinyl)phenyl]amino]carbonyl]-2-thienyl]-, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CH 1

CRN 196204-14-5
 CMF C23 H24 N4 O5 S2

L8 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CH 2

CRN 76-05-1
 CMF C2 H F3 O2





IT 196204-13-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzene derivs. as fibrinogen receptor antagonists)

RN 196204-13-4 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[[5-[[[2-methoxy-2-oxoethyl] (phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 17 Sep 1997
 GI



AB Fibrinogen receptor antagonists of the general formula X-A-Y-Z-B [X = heterocycle; A = R1a-substituted phenylene, NR1, R1a-substituted piperidinediyl; Y = alkylene or other divalent bridging group; Z = aryl, heterocycle; B = (CH2)mNR4CH(R3)COR5; R1, R3 = independently H, C1-10 alkyl, C3-8 cycloalkyl, aryl-CO-8 alkyl, amino-CO-8 alkyl, C1-6 alkylamino-CO-8 alkyl, C1-6 dialkylamino-CO-8 alkyl, C1-3 acylamino-CO-8 alkyl, CO-6 alkyl-CO2H, CO-6 alkyl-CO2C-1-3 alkyl, CO-6 alkyl-CO2H, HO-CO-6 alkyl; R1a = any group R1, halo, oxo; R2 = any group R1, halo; R4 = (CH2)p-D-R6, Q1, Q2; Z-B = heterocyclic group Q3; D = SO2, CO; R5 = OH, C1-8 alkoxy, aryl CO-5 alkoxo, C1-8 alkylcarbonyloxy C1-4 alkoxy, aryl C1-8 alkylcarbonyloxy C1-4 alkoxy, L- or D-amino acid residue optionally esterified by C1-6 alkyl; R6 = CF3, C3-6 cycloalkyl, (un)substituted C1-6 alkyl, CO-6 alkylaryl, CO-6 alkylheterocyclyl, NR1C1-6 alkyl, NR1CO-6 alkylaryl, NR1CO-6 alkylheterocyclyl; m = 0-1; p = 0-2] and which includes, for example, compds. I, are useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, and preventing thrombus or embolus formation. Thus, sequential reaction of 4-O2NC6H4NH2 with PhSO2Cl and BrCH2CO2Et gave N-aryl-N-sulfonylglycine ester 4-O2NC6H4N(SO2Ph)CH2CO2Et (II). Catalytic reduction of II, followed by amidation with 4-(4-tert-butoxycarbonylpiperazin-1-yl)benzoyl chloride and deprotection gave desired antagonist I (Y = CONH, D = SO2, R1 = R1a = R2 = R3 = H; R5 = OH, R6 = Ph).


ACCESSION NUMBER: 1997:594724 HCAPLUS
 DOCUMENT NUMBER: 127:263057
 TITLE: Preparation of heterocyclic fibrinogen receptor antagonists
 INVENTOR(S): Wai, John; Duggan, Mark E.; Fisher, Thorsten E.; Hartman, George D.; Perkins, James J.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Wai, John; Duggan, Mark E.; Fisher, Thorsten E.; Hartman, George D.; Perkins, James J.
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

L8 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9731910 | A1 | 19970904 | WO 1997-US2712 | 19970224 |
| V: AU, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CN, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2246756 | AA | 19970904 | CA 1997-2246756 | 19970224 |
| AU 9721332 | A1 | 19970916 | AU 1997-21332 | 19970224 |
| AU 712082 | B2 | 19991028 | | |
| EP 885205 | A1 | 19981223 | EP 1997-906712 | 19970224 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| JP 2000505471 | T2 | 20000509 | JP 1997-531013 | 19970224 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 1996-12380P | P 19960228 |
| | | | GB 1996-6489 | A 19960327 |
| | | | WO 1997-US2712 | W 19970224 |


OTHER SOURCE(S): MARPAT 127:263057

IT 196204-14-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic fibrinogen receptor antagonists)
 RN 196204-14-5 HCAPLUS
 CN Glycine, N-(phenylsulfonyl)-N-[5-[[[4-(1-piperazinyl)phenyl]amino]carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)



IT 196204-13-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocyclic fibrinogen receptor antagonists)
 RN 196204-13-4 HCAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[[5-[(2-methoxy-2-oxoethyl)(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



Ngrazier 10781442clmland6


RN 409364-73-4 HCAPLUS

CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-2-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409364-81-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-4-methyl-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 23 Jan 2000

GI

AB The title compds. [I; A1 = (un)substituted phenylene, naphthylene, heteroarylene; ring A2 comprises the carbon atoms which carry the groups C(:X)NH and NHSO₂R₂ is a benzene, naphthalene, (un)saturated 3-7 membered carbocycle, etc.; R₁ = (un)substituted aryl, heterocyclyl, C1-18 alkyl; R₂ = (un)substituted aryl, heterocyclyl, C1-10 alkyl, etc.; R₃ = H, halo, CF₃, etc.; n = 0-2; X = O, NH], useful for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis, were prepared. The compds. I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. Thus, reacting 4-{[2-(4-chlorophenylsulfonyl)-4,5-dimethoxybenzoyl]amino}benzenesulfonyl fluoride (preparation given) with thiomorpholine afforded 65% II which showed 34.8-fold stimulation ([cGMP]test substance/[cGMP]control) at 50 µM.

ACCESSION NUMBER: 2000:53572 HCAPLUS

DOCUMENT NUMBER: 132:93104

TITLE: Preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production

INVENTOR(S): Schindler, Ursula; Schonafinger, Karl; Strobel, Hartmut

PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2000002851 | A1 | 20000120 | WO 1999-EP4426 | 19990625 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 19830430 | A1 | 20000113 | DE 1998-19830430 | 19980708 |
| DE 19903126 | A1 | 20000803 | DE 1999-19903126 | 19990127 |
| CA 2336807 | AA | 20000120 | CA 1999-2336807 | 19990625 |
| AU 9946160 | A1 | 20000201 | AU 1999-46160 | 19990625 |
| AU 761983 | B2 | 20030612 | | |
| BR 9911914 | A | 20010327 | BR 1999-11914 | 19990625 |
| EP 1095016 | A1 | 20010502 | EP 1999-929318 | 19990625 |
| EP 1095016 | B1 | 20051109 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| JP 2002520309 | T2 | 20020709 | JP 2000-559082 | 19990625 |
| RU 2234497 | C2 | 20040820 | RU 2001-103645 | 19990625 |
| AT 309206 | E | 20051115 | AT 1999-929318 | 19990625 |
| NO 2001000013 | A | 20010301 | NO 2001-13 | 20010102 |
| PRIORITY APPLN. INFO.: | | | DE 1998-19830430 | A 19980708 |
| | | | DE 1999-19903126 | A 19990127 |
| | | | WO 1999-EP4426 | W 19990625 |


OTHER SOURCE(S): MARPAT 132:93104

IT 254877-23-1P 254877-27-5P 254878-40-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production)


RN 254877-23-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254877-27-5 HCAPLUS




CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254878-40-5 HCAPLUS

CN Benzenesulfonyl fluoride, 4-[[[3-[[(4-chlorophenyl)sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 12 Apr 2002
 GI



AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

ACCESSION NUMBER: 2002:275753 HCAPLUS
 DOCUMENT NUMBER: 136:309843
 TITLE: Preparation of thiophenes as phosphate transport inhibitors
 INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2002028353 | A2 | 20020411 | WO 2001-US31318 | 20011005 |
| WO 2002028353 | A3 | 20020711 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002013048 A5 20020415 AU 2002-13048 20011005
PRIORITY APPLN. INFO.: US 2000-238068P P 20001005
WO 2001-US31318 W 20011005

OTHER SOURCE(S): MARPAT 136:309843
IT 409361-90-6P 409361-91-7P 409361-92-8P
409361-93-9P 409361-94-0P 409361-99-5P
409362-00-1P 409362-01-2P 409362-02-3P
409362-03-4P 409362-04-5P 409362-05-6P
409362-06-7P 409362-11-4P 409362-12-5P
409362-13-6P 409362-14-7P 409362-17-0P
409362-18-1P 409362-19-2P 409362-20-5P
409362-22-7P 409362-28-3P 409362-29-4P
409362-30-7P 409362-31-8P 409362-32-9P
409362-33-0P 409362-34-1P 409362-35-2P
409362-36-3P 409362-37-4P 409362-38-5P
409362-39-6P 409362-40-9P 409362-41-0P
409362-42-1P 409362-43-2P 409362-44-3P
409362-45-4P 409362-46-5P 409362-47-6P
409362-48-7P 409362-49-8P 409362-50-1P
409362-51-2P 409362-52-3P 409362-53-4P
409362-54-5P 409362-55-6P 409362-56-7P
409362-57-8P 409362-58-9P 409362-59-0P
409362-60-3P 409362-61-4P 409362-62-5P
409362-63-6P 409362-64-7P 409362-65-8P
409362-66-9P 409362-67-0P 409362-68-1P
409362-69-2P 409362-70-5P 409362-71-6P
409362-72-7P 409362-73-8P 409362-75-0P
409362-76-1P 409362-77-2P 409362-78-3P
409362-81-8P 409362-82-9P 409362-83-0P
409362-84-1P 409362-85-2P 409362-87-4P
409362-93-2P 409362-95-4P 409362-97-6P
409362-98-7P 409363-00-4P 409363-01-5P
409363-02-6P 409363-03-7P 409363-04-8P
409363-05-9P 409363-06-0P 409363-07-1P
409363-08-2P 409363-10-6P 409363-15-1P
409363-17-3P 409363-19-5P 409363-21-9P
409363-25-3P 409363-27-5P 409363-28-6P
409363-29-7P 409363-30-0P 409363-31-1P
409363-32-2P 409363-35-5P 409363-36-6P
409363-41-3P 409363-51-5P 409363-52-6P
409363-53-7P 409363-54-8P 409363-57-1P
409363-58-2P 409363-59-3P 409363-60-6P
409363-61-7P 409363-62-8P 409363-63-9P
409363-64-0P 409363-65-1P 409363-66-2P
409363-67-3P 409363-69-5P 409363-70-8P
409363-71-9P 409363-72-0P 409363-73-1P
409363-74-2P 409363-75-3P 409363-76-4P
409363-77-5P 409363-78-6P 409363-79-7P
409363-80-0P 409363-81-1P 409363-82-2P
409363-83-3P 409363-84-4P 409363-85-5P
409363-86-6P 409363-87-7P 409363-88-8P
409363-89-9P 409363-90-2P 409363-91-3P
409363-92-4P 409363-93-5P 409363-94-6P
409363-95-7P 409363-96-8P 409363-97-9P
409363-98-0P 409363-99-1P 409364-00-7P
409364-01-8P 409364-02-9P 409364-03-0P
409364-04-1P 409364-05-2P 409364-06-3P
409364-29-0P 409364-31-4P 409364-33-6P
409364-35-8P 409364-37-0P 409364-39-2P


409364-41-6P 409364-43-8P 409364-45-0P
409364-47-2P 409364-49-4P 409364-51-8P
409364-53-0P 409364-54-1P 409364-56-3P
409364-64-3P 409364-65-4P 409364-66-5P
409364-67-6P 409364-68-7P 409364-69-8P
409364-70-1P 409364-71-2P 409364-72-3P
409364-73-4P 409364-81-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of thiophenes as phosphate transport inhibitors)


RN 409361-90-6 HCAPLUS

CN 3-Thiophenecarboxamide, N-(3-chlorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409361-91-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409361-92-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[2-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409361-93-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409361-94-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409361-99-5 HCAPLUS


CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[3-(trifluoromethyl)phenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-00-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-01-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[2-fluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-02-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[2-

fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-03-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[4-(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-04-5 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[4-(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-05-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)



RN 409362-06-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409362-11-4 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-12-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-13-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-14-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-17-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(trifluoromethyl)phenyl]-3-[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409362-18-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[2-fluorophenyl]sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-19-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl) sulfonyl] amino]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 409362-20-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl) sulfonyl] amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-22-7 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl) amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-28-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-29-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(1-methylethyl)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-30-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-phenoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-31-8 HCAPLUS


CN 2-Thiophenecarboxamide, N-[4-(hexyloxy)phenyl]-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-32-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-methoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-33-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-methylethoxy)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-34-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-acetylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-35-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-benzoylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-36-3 HCAPLUS

CN Benzeneacetic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 409362-37-4 HCAPLUS

CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)




RN 409362-38-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(1-oxopropyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-39-6 HCAPLUS

CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 409362-40-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(2-hydroxyethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-41-0 HCAPLUS


CN 2-Thiophenecarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-42-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(diethylamino)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-43-2 HCAPLUS
 CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 409362-44-3 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-
 trifluorophenyl)- (9CI) (CA INDEX NAME)




RN 409362-45-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-[(1H-indazol-6-ylamino)sulfonyl]phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-46-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 409362-47-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(hydroxymethyl)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-48-7 HCAPLUS


CN 2-Thiophenecarboxamide, N-(4-cyclohexylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-49-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-{4-(phenylmethoxy)phenyl}-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-50-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-fluorophenyl)-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409362-51-2 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-52-3 HCAPLUS
 CN 2-Thiophenecarboxamide, N-phenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-53-4 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 409362-54-5 HCAPLUS
 CN Benzoic acid, 2-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 409362-55-6 HCAPLUS
 CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-56-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,6-difluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-57-8 HCAPLUS
CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409362-58-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-59-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-1,3-benzodioxol-5-yl-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-60-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-61-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-62-5 HCAPLUS


CN 2-Thiophenecarboxamide, N-(2-benzoyl-4-chlorophenyl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-63-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(1H-indol-2-yl)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-64-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-5-isoquinolinyl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)




RN 409362-65-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-2-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)




RN 409362-66-9 HCAPLUS
 CN 2-Thiophenecarboxamide, N-9H-fluoren-2-yl-3-[(phenylsulfonyl)amino]- (9CI)
 (CA INDEX NAME)



RN 409362-67-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[(phenylamino)carbonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-68-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-69-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-2-yl-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-70-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-fluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-71-6 HCAPLUS

CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
ethyl ester (9CI) (CA INDEX NAME)




RN 409362-72-7 HCAPLUS


CN 2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-73-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-75-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409362-76-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-acetylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-77-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-78-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-6-quinolinyl- (9CI)
(CA INDEX NAME)




RN 409362-81-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(phenylmethoxy)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409362-82-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-1-
naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409362-83-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,5-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-84-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(1H-pyrrol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 409362-85-2 HCAPLUS


CN 2-Thiophenecarboxamide, N-1H-indazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)




RN 409362-87-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-fluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-93-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-ethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)




RN 409362-95-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



Ngrazier 10781442clm1and6


RN 409362-97-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dimethylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409362-98-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409363-00-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-01-5 HCAPLUS


CN 2-Thiophenecarboxamide, N-1H-benzotriazol-5-yl-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409363-02-6 HCAPLUS
 CN Benzoic acid, 2-methoxy-5-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-03-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(2-methyl-6-benzothiazolyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-04-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(1,3-dihydro-5-isobenzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-05-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-06-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(2-methyl-4-pyrimidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-07-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-[3-(5-oxazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-08-2 HCAPLUS


CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-5-quinolinyl- (9CI) (CA INDEX NAME)




RN 409363-10-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chlorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409363-15-1 HCAPLUS
CN Benzoic acid, 4-methoxy-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409363-17-3 HCAPLUS
CN Benzoic acid, 4-methyl-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 409363-19-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(phenylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-21-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)




RN 409363-25-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 409363-27-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1H-inden-5-yl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-28-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-29-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indol-5-yl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)




RN 409363-30-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(dimethylamino)phenyl]-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-31-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2-methoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409363-32-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2-methylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409363-35-5 HCAPLUS


CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-
[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 409363-36-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409363-41-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-51-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(phenylmethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-52-6 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-3-yl-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)



RN 409363-53-7 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[4-(4-chlorophenoxy)phenyl]-3-
 [(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-54-8 HCAPLUS
 CN 2-Thiophenecarboxamide, N-[2-(methylthio)phenyl]-3-[(phenylsulfonyl)amino]-
 (9CI) (CA INDEX NAME)




RN 409363-57-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-1-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI)
(CA INDEX NAME)




RN 409363-58-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[[2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-59-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-60-6 HCAPLUS


CN 2-Thiophenecarboxamide, N-(2,3-dihydro-5-benzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-61-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chloro-3-methylphenyl)-3-
[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409363-62-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-8-
oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 409363-63-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[3-
(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-64-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-65-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[3-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-66-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-67-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-69-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-70-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-71-9 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-72-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[3,4-difluorophenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-73-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chloro-3,5-dimethylphenyl) sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-74-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-bromophenyl) sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-75-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-76-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-77-5 HCAPLUS


CN 2-Thiophenecarboxamide, 3-[[[3-chloro-4-fluorophenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-78-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[5-fluoro-2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-79-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,5-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



Ngrazier 10781442clm1and6


RN 409363-80-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3-chloro-2-methylphenyl) sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-81-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,4-dichlorophenyl) sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-82-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluorophenyl) sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-83-3 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[(2-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)]- (9CI) (CA INDEX NAME)




RN 409363-84-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[(2-bromophenyl)sulfonyl]amino]-N-(3-chlorophenyl)]- (9CI) (CA INDEX NAME)




RN 409363-85-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,6-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-86-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-iodophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-87-7 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-88-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-89-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[4-acetylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



Ngrazier 10781442clm1and6


RN 409363-90-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(2-chloro-4-cyanophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 409363-91-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-cyanophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-92-4 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-93-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,5-dichloro-4-hydroxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-94-6 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,5-dimethoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



Ngrazier 10781442clmland6


RN 409363-95-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-96-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-methoxy-5-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409363-97-9 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[3,5-difluoro-4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-98-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2-methylphenyl]sulfonylamino]- (9CI) (CA INDEX NAME)




RN 409363-99-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,5-dimethylphenyl]sulfonylamino]- (9CI) (CA INDEX NAME)



RN 409364-00-7 HCAPLUS


Ngrazier 10781442clm1and6

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-01-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-methylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-02-9 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-ethylphenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-03-0 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[2,4,6-trimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-04-1 HCAPLUS
 CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(2-naphthalenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-05-2 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(1-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 409364-06-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-29-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[[(3,4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 409364-31-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[3,4-difluorophenyl)sulfonyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 409364-33-6 HCAPLUS


CN 2-Thiophenecarboxamide, 3-[[3,4-difluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



Ngrazier 10781442clm1and6


RN 409364-35-8 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-37-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-39-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(hexyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-41-6 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[[3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-43-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-45-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-47-2 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 409364-49-4 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




Ngrazier 10781442clmland6




RN 409364-51-8 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[[3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-53-0 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[3,4-difluorophenyl)sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 409364-54-1 HCAPLUS

CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-56-3 HCAPLUS


CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-64-3 HCAPLUS


CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-5-(4-fluorophenyl)-3-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

Ngrazier 10781442clm1and6




RN 409364-65-4 HCAPLUS

CN [2,2'-Bithiophene]-5-carboxamide, N-(3-chlorophenyl)-4-[[2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)




RN 409364-66-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[4-chlorophenyl)sulfonyl]amino]-4-methyl- (9CI) (CA INDEX NAME)




RN 409364-67-6 HCAPLUS


CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409364-68-7 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3,5-difluorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409364-69-8 HCAPLUS
CN 3-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)




RN 409364-70-1 HCAPLUS

CN 3-Thiophenecarboxamide, N-(4-fluorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409364-71-2 HCAPLUS

CN 3-Thiophenecarboxamide, N-(3-fluorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409364-72-3 HCAPLUS

CN 3-Thiophenecarboxamide, 4-[[(3,4-difluorophenyl) sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

